Brought to you by:
TOBA III clinical trial results published
Intact Vascular has announced the peer-reviewed publication of its Tack optimized balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery. The multi-center, single-arm, prospective study investigated the combination of the Tack endovascular system with Medtronic’s IN.PACT Admiral drug-coated balloon as…
Technology drives vascular future
Decades ago, “picture” phones were an idea straight out of science fiction. As the saying goes, the future is now. FaceTime and Skype are common; similar technology permits doctors to visit patients via telemedicine. In other health technological advancements, “wearables”…
Quality: Global Vascular Guidelines pocket guide coming soon
The Global Vascular Guidelines (GVG), extensively researched and written by an international committee of leading vascular experts, will soon be available as a pocket guide. The guidelines recommend the use of the Society for Vascular Surgery (SVS) Threatened Limb Classification…
Clopidogrel exposure along with aspirin and rivaroxaban should be ‘minimized or avoided’ in PAD revascularization
“More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence of clear benefit, clopidogrel exposure along with aspirin and rivaroxaban should be minimized or avoided to…
Combining aspirin with rivaroxaban reduces risk equally in presence or absence of diabetes
In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular and peripheral endpoints in patients with and without diabetes, a prespecified analysis of the COMPASS trial has shown. It also noted…
Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization
Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with aspirin alone. The VOYAGER PAD study was…